SCHEMBL3077836

SCHEMBL3077836

O=C1c2ccccc2C(=O)N1Cc1cn2ccccc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.50
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 1/20 0.50
PKM P14618 1/20 0.50
KMT2A Q03164 1/20 0.50
NPC1 O15118 6/20 0.49
RAB9A P51151 6/20 0.49
TSHR P16473 2/20 0.49
HSD17B10 Q99714 1/20 0.49
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 7/20 0.47
HTR1A P08908 2/20 0.46
DRD2 P14416 2/20 0.46
DRD4 P21917 2/20 0.46
ADRA1D P25100 2/20 0.46
ADRA1A P35348 2/20 0.46
ADRA1B P35368 2/20 0.46
DRD3 P35462 2/20 0.46
TP53 P04637 2/20 0.46
MAPT P10636 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL949224 0.85 HSD17B10 (0.52) KDM4EALDH1A1MEN1PKMKMT2A
SCHEMBL22499046 0.82 METTL3 (0.47) KDM4EALDH1A1MEN1PKMKMT2A
SCHEMBL23530592 0.81 ALDH1A1 (0.47) KDM4EALDH1A1MEN1PKMKMT2A
SCHEMBL23530739 0.79 MEN1 (0.42) KDM4EALDH1A1MEN1PKMKMT2A
SCHEMBL24737349 0.78 MEN1 (0.43) ALDH1A1MEN1PKMKMT2AADRA1D
SCHEMBL29830221 0.77 METTL3 (0.48) KDM4EALDH1A1MEN1PKMKMT2A
SCHEMBL27030381 0.77 METTL3 (0.48) KDM4EALDH1A1MEN1PKMKMT2A
SCHEMBL9796680 0.76 TDP1 (0.51) KDM4EALDH1A1PKMNPC1RAB9A
SCHEMBL8176725 0.76 RAB9A (0.54) KDM4EALDH1A1MEN1PKMKMT2A
SCHEMBL9570362 0.75 KDM4E (0.56) KDM4EALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875026-B1 IMIDAZOPYRIDINE DERIVATIVE USED IN THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-09-21 EP disclosed
EP-2875026-B1 IMIDAZOPYRIDINE DERIVATIVE USED IN THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-09-21 EP disclosed
US-9381191-B2 Imidazopyridine derivatives useful in treating diabetes METABRAIN RESEARCH (FR) 2016-07-05 US disclosed
US-9381191-B2 Imidazopyridine derivatives useful in treating diabetes METABRAIN RESEARCH (FR) 2016-07-05 US disclosed
US-9381191-B2 Imidazopyridine derivatives useful in treating diabetes METABRAIN RESEARCH (FR) 2016-07-05 US disclosed
US-20150182507-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL IN TREATING DIABETES METABRAIN REDEARCH (FR) 2015-07-02 US disclosed
US-20150182507-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL IN TREATING DIABETES METABRAIN REDEARCH (FR) 2015-07-02 US disclosed
US-20150182507-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL IN TREATING DIABETES METABRAIN REDEARCH (FR) 2015-07-02 US disclosed
US-20100227880-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2010-09-09 US disclosed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed
EP-1124811-A1 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.p.A. (IT) 2001-08-22 EP disclosed
WO-2000026203-A1 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227880-A1 CHEMICAL COMPOUNDS CYP3A5, SLC10A1, ABCB11 KDM4E 2460/4885ALDH1A1 210/4885MEN1 627/4885
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 KDM4E 2087/4885ALDH1A1 903/4885MEN1 1294/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 KDM4E 2087/4885ALDH1A1 903/4885MEN1 1294/4885
US-20150182507-A1 IMIDAZOPYRIDINE DERIVATIVES USEFUL IN TREATING DIABETES IAPP, SLC5A2, GPR119 KDM4E 3434/4885ALDH1A1 206/4885MEN1 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.